Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PharmaCyte Biotech, Inc. (PMCB)
USD0.71
+0.02 (+2.35%)
US NASDAQ Healthcare Biotechnology
Address
3960 Howard Hughes Parkway 89169
Las Vegas, NV, US
Las Vegas, NV, US
CEO
Joshua N. Silverman
Website
pharmacyte.com
IPO
2013-01-02
CIK 1157075 ISIN US71715X2036
Description
PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells. This innovative platform serves as the foundation for treatments aimed at diverse cancers, such as advanced and inoperable pancreatic cancer, as well as diabetes. The company's pipeline includes therapies for pancreatic and other solid cancerous tumors; a treatment for Type 1 and insulin-dependent Type 2 diabetes involving encapsulated, genetically modified insulin-producing cells; and cancer treatments derived from cannabis plant compounds. To further its research, PharmaCyte maintains collaborative agreements: one with the University of Technology, Sydney, for the creation of melligen cells to combat diabetes, and another with the University of Northern Colorado, focusing on methods for identifying, separating, and quantifying cannabis constituents. Originally established in 1996, the company operated under the name Nuvilex, Inc. before rebranding as PharmaCyte Biotech, Inc. in January 2015. Its corporate headquarters are located in Las Vegas, Nevada.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.71
+0.02 (+2.35%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
180.3K
Beta
0.52
Float Shares
5.51M
Free Float %
81.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.67% | +4.75% | +15.57% | +20.91% | +7.86% | +15.25% | -22.02% | -73.51% | -95.83% | -99.23% | -98.55% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Hold
Price Targets & DCF
Current price
0.71
DCF (Unlevered)
2.49
+253.4%
DCF (Levered)
2.07
+193.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-2.67
Distress
Piotroski F-Score
0 / 9
Weak
MOAT Score
4 / 10
Developing
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✓ MOAT relativo
★ Strong MOAT
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+277.2% ★ Q1'26: +61.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%— ★
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%+84.3% ★ Q1'26: -45.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-23.5% ★ Q1'26: +33.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× ★ Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Apr 2025 actual |
|---|---|
| Revenue |
—
|
| EBITDA |
30.66M
|
| EBIT |
30.66M
|
| Net Income |
30.66M
|
| SGA |
3.94M
|
| EPS |
3.19
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-26 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-19 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-18 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-15 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-14 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-13 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-3.34M
OE per share TTM
-5.89
Owner's Yield
-43.21%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
26.6%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
32
Total invested
643.2K
Insider transactions (90d)
0
Beneficial owners (>5%)
19
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Brown Stone Capital, LP | 95.26M | 5.80% | — | 95.26M | — | 95.26M | PN | — | 2020-05-06 | ↗ |
| 2 | Inc. | 95.26M | 5.80% | — | 95.26M | — | 95.26M | CO | — | 2020-05-06 | ↗ |
| 3 | Nima Montazeri | 95.26M | 5.80% | — | 95.26M | — | 95.26M | IN | — | 2020-05-06 | ↗ |
| 4 | PharmaCyte Biotech, Inc. | 12.71M | 37.00% | 12.71M | — | 12.71M | 10.00 | CO | Nevada | 2023-11-22 | ↗ |
| 5 | NAME OF REPORTING PERSONS | 1.25M | 9.00% | — | 1.25M | — | 1.25M | — | Cayman Islands | 2021-08-30 | ↗ |
| 6 | Daniel B. Asher | 1.23M | 5.60% | — | 1.23M | — | 1.23M | HC, IN | United States of America | 2022-02-11 | ↗ |
| 7 | Intracoastal Capital LLC | 1.23M | 5.60% | — | 1.23M | — | 1.23M | OO | Delaware | 2022-02-11 | ↗ |
| 8 | Mitchell P. Kopin | 1.23M | 5.60% | — | 1.23M | — | 1.23M | HC, IN | United States of America | 2022-02-11 | ↗ |
| 9 | Richard Abbe | 1.05M | 5.10% | — | — | 68.4K | 10.00 | IN | OR PLACE OF ORGANIZATION | 2021-11-04 | ↗ |
| 10 | Shay Capital Holdings LLC | 1.04M | 5.00% | 1.04M | — | 1.04M | — | IA | Delaware | 2022-10-20 | ↗ |
| 11 | Shay Capital LLC | 1.04M | 5.00% | 1.04M | — | 1.04M | — | CO | Delaware | 2022-10-20 | ↗ |
| 12 | Iroquois Capital Management, LLC | 980.3K | 4.70% | — | — | — | 10.00 | OO | OR PLACE OF ORGANIZATION | 2021-11-04 | ↗ |
| 13 | Iroquois Master Fund Ltd. | 980.3K | 4.70% | — | — | — | 10.00 | CO | OR PLACE OF ORGANIZATION | 2021-11-04 | ↗ |
| 14 | Kimberly Page | 980.3K | 4.70% | — | — | — | 10.00 | IN | OR PLACE OF ORGANIZATION | 2021-11-04 | ↗ |
| 15 | Capital LLC | 956.2K | 9.90% | 956.2K | — | 956.2K | — | IA | Delaware | 2024-02-14 | ↗ |
| 16 | Khatri | 956.2K | 9.90% | 956.2K | — | 956.2K | — | IN | States | 2024-02-14 | ↗ |
| 17 | Opportunity Master Fund, SPC – Segregated Master Portfolio B | 956.2K | 9.90% | 956.2K | — | 956.2K | — | CO | Islands | 2024-02-14 | ↗ |
| 18 | Iroquois Capital Investment Group LLC | 68.4K | 0.30% | — | — | 68.4K | 10.00 | OO | OR PLACE OF ORGANIZATION | 2021-11-04 | ↗ |
| 19 | SCHEDULE 13D | — | 14.00% | — | — | 212.00 | — | CO | — | 2024-05-30 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
32
+5 vs prev Q
New positions
11
Closed positions
6
Increased
17
Reduced
7
Put/Call ratio
0.00
Calls held
160.2K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 186.1K +175.5K (+1,655.7%) | 134.7K +124.5K (+1,210.9%) | 2.74% +2.583 pp | 0.00% +0.000 pp | USD0.74 -2.7% | 5 qtrs — |
| 2 | HRT FINANCIAL LP | 182.8K +182.8K (+100.0%) | 132.0K +132.0K (+100.0%) | 2.69% +2.690 pp | 0.00% +0.000 pp | USD0.72 +0.0% | 1 qtrs NEW |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 123.8K -2.8K (-2.2%) | 89.7K -33.1K (-27.0%) | 1.82% -0.041 pp | 0.00% +0.000 pp | USD2.63 -72.6% | 18 qtrs — |
| 4 | SABBY MANAGEMENT, LLC | 100.0K +100.0K (+100.0%) | 72.4K +72.4K (+100.0%) | 1.47% +1.472 pp | 0.10% +0.104 pp | USD0.72 +0.0% | 1 qtrs NEW |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 94.0K +14.0K (+17.5%) | 68.1K -9.5K (-12.2%) | 1.38% +0.207 pp | 0.00% +0.000 pp | USD1.75 -58.9% | 11 qtrs — |
| 6 | VANGUARD GROUP INC | 74.9K +— (+0.0%) | 54.2K -18.4K (-25.4%) | 1.10% +0.000 pp | 0.00% +0.000 pp | USD2.45 -70.6% | 17 qtrs — |
| 7 | NORTHERN TRUST CORP | 35.6K +16.4K (+85.3%) | 25.8K +7.2K (+38.4%) | 0.52% +0.241 pp | 0.00% +0.000 pp | USD1.67 -56.9% | 17 qtrs — |
| 8 | SCHONFELD STRATEGIC ADVISORS LLC | 26.2K -22.0 (-0.1%) | 19.0K -6.5K (-25.4%) | 0.39% 0.000 pp | 0.00% 0.000 pp | USD2.99 -75.9% | 18 qtrs — |
| 9 | SIMPLEX TRADING, LLC | 25.8K +24.7K (+2,248.5%) | 18.7K +17.7K (+1,770.3%) | 0.38% +0.364 pp | 0.00% +0.000 pp | USD0.73 -1.4% | 2 qtrs — |
| 10 | TWO SIGMA SECURITIES, LLC | 24.6K +24.6K (+100.0%) | 17.8K +17.8K (+100.0%) | 0.36% +0.361 pp | 0.00% +0.002 pp | USD0.72 +0.0% | 1 qtrs NEW |
| 11 | XTX TOPCO LTD | 24.4K +24.4K (+100.0%) | 17.7K +17.7K (+100.0%) | 0.36% +0.360 pp | 0.00% +0.001 pp | USD0.72 +0.0% | 1 qtrs NEW |
| 12 | EQUITEC PROPRIETARY MARKETS, LLC | 22.2K -60.5K (-73.1%) | 16.1K -64.1K (-79.9%) | 0.33% -0.890 pp | 0.01% -0.009 pp | USD2.36 -69.5% | 17 qtrs — |
| 13 | JANE STREET GROUP, LLC | 11.4K +11.4K (+100.0%) | 8.2K +8.2K (+100.0%) | 0.17% +0.168 pp | 0.00% +0.000 pp | USD0.72 +0.0% | 1 qtrs NEW |
| 14 | TOWER RESEARCH CAPITAL LLC (TRC) | 4.9K -653.0 (-11.8%) | 3.5K -1.8K (-34.1%) | 0.07% -0.010 pp | 0.00% 0.000 pp | USD1.41 -48.9% | 18 qtrs — |
| 15 | UBS GROUP AG | 2.7K +1.4K (+107.6%) | 2.0K +705.0 (+54.9%) | 0.04% +0.021 pp | 0.00% +0.000 pp | USD0.97 -25.8% | 13 qtrs — |
| 16 | BANK OF AMERICA CORP /DE/ | 314.00 -224.0 (-41.6%) | 227.00 -295.0 (-56.5%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD1.23 -41.5% | 15 qtrs — |
| 17 | ADVISOR GROUP HOLDINGS, INC. | 303.00 -1.0 (-0.3%) | 219.00 -75.0 (-25.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.12 -35.7% | 18 qtrs — |
| 18 | SACHETTA, LLC | 14.00 +— (+0.0%) | 11.00 -3.0 (-21.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.14 -66.4% | 9 qtrs — |
| 19 | AVISO FINANCIAL INC. | 12.00 +12.0 (+100.0%) | 8.00 +8.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.67 +7.5% | 1 qtrs NEW |
| 20 | BFSG, LLC | 5.00 +— (+0.0%) | 4.00 -1.0 (-20.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.40 -70.0% | 8 qtrs — |
| 21 | FINANCIAL CONSULATE, INC | 2.00 +— (+0.0%) | 2.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.50 +44.0% | 2 qtrs — |
| 22 | MORGAN STANLEY | 2.00 -7.0 (-77.8%) | 2.00 -8.0 (-80.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.00 -28.0% | 18 qtrs — |
| 23 | NEWEDGE ADVISORS, LLC | 2.00 +— (+0.0%) | 1.00 -1.0 (-50.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 -64.0% | 12 qtrs — |
| 24 | BLACKROCK, INC. | 1.00 +— (+0.0%) | 1.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs — |
| 25 | IFP ADVISORS, INC | 1.00 +— (+0.0%) | 1.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 -28.0% | 4 qtrs — |
| 26 | MCF ADVISORS LLC | 1.00 +1.0 (+100.0%) | 1.00 +1.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 1 qtrs NEW |
| 27 | CITIGROUP INC | — -1.0 (-100.0%) | — -1.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 46.3K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
10
Sells
0
Shares acquired
636.7K
Shares disposed
—
Cash buys
6.00
Cash sales
—
Net activity
+636,680
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | WEINSTEIN ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 119,170 | 0.67 | 79.8K | 119,170 | D | ↗ |
| 2026-03-31 | WALKER WAYNE REMELL | Director | A-Award | A | Stock Option (Right to Buy) | 119,170 | 0.67 | 79.8K | 119,170 | D | ↗ |
| 2026-03-31 | SCHECHTER JONATHAN | Director | A-Award | A | Stock Option (Right to Buy) | 119,170 | 0.67 | 79.8K | 119,170 | D | ↗ |
| 2026-03-31 | Abecassis Michael M | Director | A-Award | A | Stock Option (Right to Buy) | 119,170 | 0.67 | 79.8K | 119,170 | D | ↗ |
| 2026-01-07 | Silverman Joshua | Director / Officer | P-Purchase | A | Common Stock | 40,000 | 0.83 | 33.3K | 416,250 | D | ↗ |
| 2026-01-07 | SCHECHTER JONATHAN | Director | P-Purchase | A | Common Stock | 20,000 | 0.84 | 16.9K | 192,500 | D | ↗ |
| 2026-01-06 | Silverman Joshua | Director / Officer | P-Purchase | A | Common Stock | 30,000 | 0.79 | 23.7K | 376,250 | D | ↗ |
| 2026-01-06 | SCHECHTER JONATHAN | Director | P-Purchase | A | Common Stock | 20,000 | 0.79 | 15.8K | 172,500 | D | ↗ |
| 2026-01-05 | Silverman Joshua | Director / Officer | P-Purchase | A | Common Stock | 30,000 | 0.78 | 23.5K | 346,250 | D | ↗ |
| 2026-01-05 | SCHECHTER JONATHAN | Director | P-Purchase | A | Common Stock | 20,000 | 0.78 | 15.6K | 152,500 | D | ↗ |
| 2025-12-12 | WEINSTEIN ROBERT | Director | F-InKind | D | Common Stock | 33,750 | 1.02 | 34.4K | 41,250 | D | ↗ |
| 2025-12-12 | WALKER WAYNE REMELL | Director | F-InKind | D | Common Stock | 16,875 | 1.02 | 17.2K | 20,625 | D | ↗ |
| 2025-12-12 | Silverman Joshua | Director / Officer | F-InKind | D | Common Stock | 258,750 | 1.02 | 263.9K | 316,250 | D | ↗ |
| 2025-12-12 | SCHECHTER JONATHAN | Director | F-InKind | D | Common Stock | 67,500 | 1.02 | 68.9K | 132,500 | D | ↗ |
| 2025-12-12 | Abecassis Michael M | Director | F-InKind | D | Common Stock | 16,875 | 1.02 | 17.2K | 22,292 | D | ↗ |
| 2025-04-25 | WEINSTEIN ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 63,233 | 1.22 | 77.1K | 63,233 | D | ↗ |
| 2025-04-25 | WALKER WAYNE REMELL | Director | A-Award | A | Stock Option (Right to Buy) | 63,233 | 1.22 | 77.1K | 63,233 | D | ↗ |
| 2025-04-25 | SCHECHTER JONATHAN | Director | A-Award | A | Stock Option (Right to Buy) | 63,233 | 1.22 | 77.1K | 63,233 | D | ↗ |
| 2025-04-25 | Abecassis Michael M | Director | A-Award | A | Stock Option (Right to Buy) | 63,233 | 1.22 | 77.1K | 63,233 | D | ↗ |
| 2024-04-30 | WEINSTEIN ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 38,009 | 2.12 | 80.6K | 38,009 | — | ↗ |
| 2024-04-30 | WALKER WAYNE REMELL | Director | A-Award | A | Stock Option (Right to Buy) | 38,009 | 2.12 | 80.6K | 38,009 | — | ↗ |
| 2024-04-30 | SCHECHTER JONATHAN | Director | A-Award | A | Stock Option (Right to Buy) | 38,009 | 2.12 | 80.6K | 38,009 | — | ↗ |
| 2024-04-30 | Abecassis Michael M | Director | A-Award | A | Stock Option (Right to Buy) | 38,009 | 2.12 | 80.6K | 38,009 | — | ↗ |
| 2023-11-20 | WEINSTEIN ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 61,248 | 2.18 | 133.5K | 61,248 | — | ↗ |
| 2023-11-20 | WALKER WAYNE REMELL | Director | A-Award | A | Stock Option (Right to Buy) | 61,248 | 2.18 | 133.5K | 61,248 | — | ↗ |
| 2023-11-20 | Trujillo Carlos | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 2.18 | 185.3K | 85,000 | — | ↗ |
| 2023-11-20 | Silverman Joshua | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 170,000 | 2.18 | 370.6K | 170,000 | — | ↗ |
| 2023-11-20 | SCHECHTER JONATHAN | Director | A-Award | A | Stock Option (Right to Buy) | 61,248 | 2.18 | 133.5K | 61,248 | — | ↗ |
| 2023-11-20 | Abecassis Michael M | Director | A-Award | A | Stock Option (Right to Buy) | 61,248 | 2.18 | 133.5K | 61,248 | — | ↗ |
| 2022-12-28 | WALKER WAYNE REMELL | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-12-28 | Farb Daniel Stuart | Director | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-12-28 | Allen Daniel | Director | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-11-14 | WEINSTEIN ROBERT | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-08-15 | Silverman Joshua | Director | — | I | Common Stock | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2022-08-15 | STOVER JACK E | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-08-15 | SCHECHTER JONATHAN | Director | — | D | Common Stock | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2022-08-15 | Farb Daniel Stuart | Director | — | D | Stock Option (short put) | 795,000 | 2.50 | 1.99M | 0 | — | ↗ |
| 2022-08-15 | Allen Daniel | Director | — | I | Common Shares | 0 | 0.00 | — | 260,000 | — | ↗ |
| 2022-03-31 | Loehr Matthias | Director | — | I | Common Stock | 0 | 0.00 | — | 3,004 | — | ↗ |
| 2021-08-10 | YUEN THOMAS C K | Director | — | D | Common Stock | 0 | 0.00 | — | 1,667 | — | ↗ |
| 2021-08-10 | Waggoner Kenneth L. | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 20,600 | — | ↗ |
| 2021-08-10 | Trujillo Carlos | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 8,800 | — | ↗ |
| 2021-08-10 | Tong Raymond CF | Director | — | D | Common Stock | 0 | 0.00 | — | 1,333 | — | ↗ |
| 2021-08-10 | Liquard Thomas | Director | — | D | Common Stock | 0 | 0.00 | — | 1,667 | — | ↗ |
| 2021-08-10 | Crabtree Gerald W | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 11,200 | — | ↗ |
| 2021-08-10 | Abecassis Michael M | Director | — | I | Common Stock | 0 | 0.00 | — | 800 | — | ↗ |
| 2021-07-01 | Abecassis Michael M | Director | — | D | Stock Option (right to buy) | 334 | 16.20 | 5.4K | 0 | — | ↗ |
| 2021-05-01 | YUEN THOMAS C K | Director | — | D | Stock Option (right to buy) | 334 | 26.55 | 8.9K | 0 | — | ↗ |
| 2021-05-01 | Liquard Thomas | Director | — | D | Stock Option (right to buy) | 334 | 26.55 | 8.9K | 0 | — | ↗ |
| 2021-01-01 | Waggoner Kenneth L. | Director / Officer | — | D | Stock Option (right to buy) | 3,000 | 10.05 | 30.2K | 0 | — | ↗ |
| 2021-01-01 | Trujillo Carlos | Director / Officer | — | D | Stock Option (right to buy) | 2,000 | 10.05 | 20.1K | 0 | — | ↗ |
| 2021-01-01 | Crabtree Gerald W | Director / Officer | — | D | Stock Option (right to buy) | 1,000 | 10.05 | 10.1K | 0 | — | ↗ |
| 2020-10-09 | Tong Raymond CF | Director | — | D | Stock Option (right to buy) | 334 | 15.57 | 5.2K | 0 | — | ↗ |
| 2020-07-01 | Abecassis Michael M | Director | — | D | Stock Option (right to buy) | 334 | 37.05 | 12.4K | 0 | — | ↗ |
| 2020-05-01 | YUEN THOMAS C K | Director | — | D | Stock Option (right to buy) | 334 | 36.00 | 12.0K | 0 | — | ↗ |
| 2020-05-01 | Liquard Thomas | Director | — | D | Stock Option (right to buy) | 334 | 36.00 | 12.0K | 0 | — | ↗ |
| 2020-01-02 | Waggoner Kenneth L. | Director / Officer | — | D | Stock Option (right to buy) | 3,000 | 61.20 | 183.6K | 0 | — | ↗ |
| 2020-01-02 | Trujillo Carlos | Director / Officer | — | D | Stock Option (right to buy) | 2,000 | 61.20 | 122.4K | 0 | — | ↗ |
| 2020-01-02 | Crabtree Gerald W | Director / Officer | — | D | Stock Option (right to buy) | 1,000 | 61.20 | 61.2K | 0 | — | ↗ |
| 2019-10-09 | Tong Raymond CF | Director | — | D | Stock Option (right to buy) | 334 | 51.00 | 17.0K | 0 | — | ↗ |
| 2019-07-01 | Abecassis Michael M | Director | — | D | Stock Option (right to buy) | 334 | 55.50 | 18.5K | 0 | — | ↗ |
| 2019-05-01 | YUEN THOMAS C K | Director | — | D | Stock Option (right to buy) | 334 | 60.60 | 20.2K | 0 | — | ↗ |
| 2019-05-01 | Liquard Thomas | Director | — | D | Stock Option (right to buy) | 334 | 60.60 | 20.2K | 0 | — | ↗ |
| 2019-03-20 | Waggoner Kenneth L. | Director / Officer | — | D | Stock Option (right to buy) | 3,000 | 74.25 | 222.8K | 0 | — | ↗ |
| 2019-03-20 | Trujillo Carlos | Director / Officer | — | D | Stock Option (right to buy) | 2,000 | 74.25 | 148.5K | 0 | — | ↗ |
| 2019-03-20 | Crabtree Gerald W | Director / Officer | — | D | Stock Option (right to buy) | 1,000 | 74.25 | 74.3K | 0 | — | ↗ |
| 2018-10-09 | Tong Raymond CF | Director | — | D | Stock Option (right to buy) | 334 | 97.35 | 32.5K | 0 | — | ↗ |
| 2018-07-01 | Abecassis Michael M | Director | — | D | Stock Option (right to buy) | 334 | 102.45 | 34.2K | 0 | — | ↗ |
| 2018-05-01 | YUEN THOMAS C K | Director | — | D | Stock Option (right to buy) | 334 | 80.85 | 27.0K | 0 | — | ↗ |
| 2018-05-01 | Liquard Thomas | Director | — | D | Stock Option (right to buy) | 334 | 80.85 | 27.0K | 0 | — | ↗ |
| 2018-01-01 | Waggoner Kenneth L. | Director / Officer | — | D | Stock Option (right to buy) | 3,000 | 83.70 | 251.1K | 0 | — | ↗ |
| 2018-01-01 | Trujillo Carlos | Director / Officer | — | D | Stock Option (right to buy) | 2,000 | 83.70 | 167.4K | 0 | — | ↗ |
| 2018-01-01 | Crabtree Gerald W | Director / Officer | — | D | Stock Option (right to buy) | 1,000 | 83.70 | 83.7K | 0 | — | ↗ |
| 2017-10-09 | Tong Raymond CF | Director | — | D | Stock Option (right to buy) | 334 | 82.95 | 27.7K | 0 | — | ↗ |
| 2017-07-03 | YUEN THOMAS C K | Director | — | D | Stock Option (right to buy) | 334 | 87.00 | 29.1K | 0 | — | ↗ |
| 2017-07-03 | Liquard Thomas | Director | — | D | Stock Option (right to buy) | 167 | 87.00 | 14.5K | 0 | — | ↗ |
| 2017-07-03 | Abecassis Michael M | Director | — | I | Stock Option (right to buy) | 800 | 87.00 | 69.6K | 0 | — | ↗ |
| 2017-03-09 | Waggoner Kenneth L. | Director / Officer | — | D | Stock Option (right to buy) | 3,000 | 156.00 | 468.0K | 0 | — | ↗ |
| 2017-03-09 | Trujillo Carlos | Director / Officer | — | D | Stock Option (right to buy) | 2,000 | 156.00 | 312.0K | 0 | — | ↗ |
| 2017-03-09 | Liquard Thomas | Director | — | D | Stock Option (right to buy) | 167 | 156.00 | 26.1K | 0 | — | ↗ |
| 2017-03-09 | Crabtree Gerald W | Director / Officer | — | D | Stock Option (right to buy) | 1,000 | 156.00 | 156.0K | 0 | — | ↗ |
| 2009-03-17 | Schmieg Martin | Director / Officer | — | D | Common stock, par value $0.0001 | 0 | 0.00 | — | 425,328 | — | ↗ |
| 2009-03-17 | BARNES MARYLEW | Director / Officer | — | D | Common stock, par value $0.0001 | 0 | 0.00 | — | 121,805 | — | ↗ |
Executive team
Top executives
Shares Outstanding
6.80M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Joshua N. Silverman Chief Executive Officer and President | 375.0K | 100.0K | — | — | — | 45.3K | 520.3K | 0.00% | ↗ |
| 2 | 2025 | Carlos A. Trujillo Chief Financial Officer | 380.0K | 50.0K | — | — | — | 52.0K | 482.0K | 0.00% | ↗ |
| 3 | 2024 | Joshua N. Silverman Chief Executive Officer and President | 375.0K | 100.0K | — | 312.9K | — | 41.7K | 829.6K | 37.72% | ↗ |
| 4 | 2024 | Carlos A. Trujillo Chief Financial Officer | 380.0K | 50.0K | — | 156.6K | — | 49.6K | 636.1K | 24.61% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joshua N. Silverman | Chief Executive Officer. President & Executive Chairman | 520.3K | male |
| Carlos A. Trujillo | Chief Financial Officer | 482.0K | male |
| Hans-Peter Hammes | Member of Medical & Scientific Advisory Board and Consultant | — | — |
| Jose L. Iglesias | Consulting Chief Medical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PMCB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
